Cancer statistics in China and United States, 2022: profiles, trends, and determinants

Changfa Xia, Xuesi Dong, He Li, Maomao Cao, Dianqin Sun, Siyi He, Fan Yang, Xinxin Yan, Shaoli Zhang, Ni Li, Wanqing Chen, Changfa Xia, Xuesi Dong, He Li, Maomao Cao, Dianqin Sun, Siyi He, Fan Yang, Xinxin Yan, Shaoli Zhang, Ni Li, Wanqing Chen

Abstract

Background: The cancer burden in the United States of America (USA) has decreased gradually. However, China is experiencing a transition in its cancer profiles, with greater incidence of cancers that were previously more common in the USA. This study compared the latest cancer profiles, trends, and determinants between China and USA.

Methods: This was a comparative study using open-source data. Cancer cases and deaths in 2022 were calculated using cancer estimates from GLOBOCAN 2020 and population estimates from the United Nations. Trends in cancer incidence and mortality rates in the USA used data from the Surveillance, Epidemiology, and End Results program and National Center for Health Statistics. Chinese data were obtained from cancer registry reports. Data from the Global Burden of Disease 2019 and a decomposition method were used to express cancer deaths as the product of four determinant factors.

Results: In 2022, there will be approximately 4,820,000 and 2,370,000 new cancer cases, and 3,210,000 and 640,000 cancer deaths in China and the USA, respectively. The most common cancers are lung cancer in China and breast cancer in the USA, and lung cancer is the leading cause of cancer death in both. Age-standardized incidence and mortality rates for lung cancer and colorectal cancer in the USA have decreased significantly recently, but rates of liver cancer have increased slightly. Rates of stomach, liver, and esophageal cancer decreased gradually in China, but rates have increased for colorectal cancer in the whole population, prostate cancer in men, and other seven cancer types in women. Increases in adult population size and population aging were major determinants for incremental cancer deaths, and case-fatality rates contributed to reduced cancer deaths in both countries.

Conclusions: The decreasing cancer burden in liver, stomach, and esophagus, and increasing burden in lung, colorectum, breast, and prostate, mean that cancer profiles in China and the USA are converging. Population aging is a growing determinant of incremental cancer burden. Progress in cancer prevention and care in the USA, and measures to actively respond to population aging, may help China to reduce the cancer burden.

Conflict of interest statement

None.

Copyright © 2022 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

Figures

Figure 1
Figure 1
Trends in cancer incidence and mortality rates by sex for China and the United States of America. Analyses were based on data released by the USA Surveillance, Epidemiology, and End Results program and the China National Cancer Center. Rates for USA cancer incidence (1975–2018) and mortality (1975–2019) were standardized by 2000 USA standard population. Rates for cancer incidence and mortality in China (2000–2015) were standardized by Segi's world standard population. CNS: Central nervous system.
Figure 2
Figure 2
Trends in determinant factors influencing cancer deaths by sex in China and the United States of America. Analyses were based on data released by the Institute for Health Metrics and Evaluation for Global Burden of Disease 2019. Cancer deaths were expressed as the product of four factors: (1) population aging, (2) population size, (3) age-specific cancer incidence rate, and (4) cancer case-fatality rate.

References

    1. Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer 2021; 127:3029–3030. doi: 10.1002/cncr.33587.
    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71:209–249. doi: 10.3322/caac.21660.
    1. Wei W, Zeng H, Zheng R, Zhang S, An L, Chen R, et al. . Cancer registration in China and its role in cancer prevention and control. Lancet Oncol 2020; 21:e342–e349. doi: 10.1016/s1470-2045(20)30073-5.
    1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. . Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66:115–132. doi: 10.3322/caac.21338.
    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022; 72:7–33. doi: 10.3322/caac.21708.
    1. Schilsky RL, Nass S, Le Beau MM, Benz EJ, Jr. Progress in cancer research, prevention, and care. N Engl J Med 2020; 383:897–900. doi: 10.1056/NEJMp2007839.
    1. National Health Commission. Healthy China Action: cancer prevention and control implementation plan (2019–2022). Beijing: National Health Commission; 2019. Available from: . [Accessed January 20, 2022]
    1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. . Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer; 2020.
    1. United Nations Department of Economic and Social Affairs Population Division. World Urbanization Prospects: The 2019 Revision. New York, USA United Nations, 2019; Available from: . [Accessed January 14, 2022]
    1. Zhang S, Sun K, Zheng R, Zeng H, Wang S, Chen R, et al. . Cancer incidence and mortality in China, 2015. J Natl Cancer Center 2021; 1:2–11. doi: 10.1016/j.jncc.2020.12.001.
    1. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Results. Seattle, WA, USA: Institute for Health Metrics and Evaluation (IHME); 2020.
    1. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. . Cancer statistics for the year 2020: an overview. Int J Cancer 2021; 149:778–789. doi: 10.1002/ijc.33588.
    1. Ferlay J, Laversanne M, Ervik M, Lam F, Colombet M, Mery L, et al. . Global Cancer Observatory: Cancer Tomorrow. Lyon, France: International Agency for Research on Cancer; 2020.
    1. Chang AY, Skirbekk VF, Tyrovolas S, Kassebaum NJ, Dieleman JL. Measuring population ageing: an analysis of the Global Burden of Disease Study 2017. Lancet Public health 2019; 4:e159–e167. doi: 10.1016/s2468-2667(19)30019-2.
    1. Xia C, Chen W. Fractions and trends of cancer burden attributable to population ageing in China (in Chinese). Chin J Oncol 2022; 44:79–85. doi: 10.3760/cma.j.cn112152-20211012-00756.
    1. Das Gupta P. Standardization and Decomposition of Rates: A User's Manual. Washington, DC, USA: US Department of Commerce Economics and Statistics Administration; 1993.
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70:7–30. doi: 10.3322/caac.21590.
    1. Vollset SE, Goren E, Yuan CW, Cao J, Smith AE, Hsiao T, et al. . Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the Global Burden of Disease Study. Lancet 2020; 396:1285–1306. doi: 10.1016/s0140-6736(20)30677-2.
    1. The State Council of the People's Republic of China. The Projects to Actively Respond to Population Aging and Nursery School Constructions During the “14th Five-Year Plan”. Beijing, China: National Development and Reform Commission; 2021.
    1. Institute for Health Metrics and Evaluation (IHME). Global Fertility, Mortality, Migration, and Population Forecasts 2017-2100. Seattle, WA, USA: Institute for Health Metrics and Evaluation (IHME); 2020.
    1. Ye P, Jin Y, Er Y, Duan L, Palagyi A, Fang L, et al. . A scoping review of national policies for healthy ageing in mainland China from 2016 to 2020. Lancet Reg Health West Pac 2021; 12:100168.doi: 10.1016/j.lanwpc.2021.100168.
    1. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J 2021; 134:783–791. doi: 10.1097/cm9.0000000000001474.
    1. Cao M, Li H, Sun D, He S, Yu Y, Li J, et al. . Cancer screening in China: the current status, challenges, and suggestions. Cancer Lett 2021; 506:120–127. doi: 10.1016/j.canlet.2021.02.017.
    1. Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, et al. . Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2019; 69:184–210. doi: 10.3322/caac.21557.
    1. Chen W, Xia C, Zheng R, Zhou M, Lin C, Zeng H, et al. . Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment. Lancet Glob Health 2019; 7:e257–e269. doi: 10.1016/s2214-109x(18)30488-1.
    1. Wang M, Luo X, Xu S, Liu W, Ding F, Zhang X, et al. . Trends in smoking prevalence and implication for chronic diseases in China: serial national cross-sectional surveys from 2003 to 2013. Lancet Respir Med 2019; 7:35–45. doi: 10.1016/s2213-2600(18)30432-6.
    1. Ward BW, Clarke TC, Nugent CN, Schiller JS. Early release of selected estimates based on data from the 2015 National Health Interview Survey. National Center for Health Statistics, 2016; Available from: . [Accessed January 21, 2022]
    1. Xia C, Zheng R, Zeng H, Zhou M, Wang L, Zhang S, et al. . Provincial-level cancer burden attributable to active and second-hand smoking in China. Tob Control 2019; 28:669–675. doi: 10.1136/tobaccocontrol-2018-054583.
    1. Thun M, Peto R, Boreham J, Lopez AD. Stages of the cigarette epidemic on entering its second century. Tob Control 2012; 21:96–101. doi: 10.1136/tobaccocontrol-2011-050294.
    1. Xia C, Qiao Y, Zhang Y, Zhao F. WHO's global strategy of cervical cancer elimination and the challenges and initiatives in China (in Chinese). Natl Med J China 2020; 100:3484–3488. doi: 10.3760/cma.j.cn112137-20200909-02606.
    1. Xia C, Xu X, Zhao X, Hu S, Qiao Y, Zhang Y, et al. . Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study. BMC Med 2021; 19:62.doi: 10.1186/s12916-021-01930-9.
    1. Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, et al. . Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob health 2018; 6:e555–e567. doi: 10.1016/s2214-109x(18)30127-x.
    1. GBD 2019 Universal Health Coverage Collaborators. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396:1250–1284. doi: 10.1016/s0140-6736(20)30750-9.
    1. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396:1204–1222. doi: 10.1016/s0140-6736(20)30925-9.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe